Cargando…

Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma

SIMPLE SUMMARY: In this study, we present a workflow to understand the modulator of ibrutinib resistance in ABC diffuse large B cell lymphoma by integrating Metabolomics and Gene expression profiling as shown in the graphical abstract. We performed an untargeted metabolomics analysis using a Q-Exact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choueiry, Fouad, Singh, Satishkumar, Sircar, Anuvrat, Laliotis, Georgios, Sun, Xiaowei, Chavdoula, Evangelia, Zhang, Shiqi, Helmig-Mason, JoBeth, Hart, Amber, Epperla, Narendranath, Tsichlis, Philip, Baiocchi, Robert, Alinari, Lapo, Zhu, Jiangjiang, Sehgal, Lalit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124963/ https://www.ncbi.nlm.nih.gov/pubmed/33946867 http://dx.doi.org/10.3390/cancers13092146

Ejemplares similares

Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma
por: Sircar, Anuvrat, et al.
Publicado: (2023)

Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy
por: Sircar, Anuvrat, et al.
Publicado: (2020)

Transcriptional regulation of amino acid metabolism by KDM2B, in the context of ncPRC1.1 and in concert with MYC and ATF4
por: Chavdoula, Evangelia, et al.
Publicado: (2023)

Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
por: George, Bhawana, et al.
Publicado: (2020)

Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
por: Denlinger, Nathan M, et al.
Publicado: (2018)

A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma
por: Hanel, Walter, et al.
Publicado: (2023)

Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-center retrospective study
por: Fleming, Megan, et al.
Publicado: (2022)

RETRACTED ARTICLE: Phosphor-IWS1-dependent U2AF2 splicing regulates trafficking of CAR-E-positive intronless gene mRNAs and sensitivity to viral infection
por: Laliotis, Georgios I., et al.
Publicado: (2021)

Retraction Note: Phosphor-IWS1-dependent U2AF2 splicing regulates trafficking of CAR-E-positive intronless gene mRNAs and sensitivity to viral infection
por: Laliotis, Georgios I., et al.
Publicado: (2021)

PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma
por: Brown-Burke, Fiona, et al.
Publicado: (2023)

Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas
por: Fleming, Megan, et al.
Publicado: (2022)

Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy
por: Annunzio, Kaitlin, et al.
Publicado: (2022)

Impact of circulating lymphoma cells at diagnosis on outcomes in patients with Waldenstrom macroglobulinemia
por: Nalin, Ansel, et al.
Publicado: (2023)

RETRACTED ARTICLE: AKT3-mediated IWS1 phosphorylation promotes the proliferation of EGFR-mutant lung adenocarcinomas through cell cycle-regulated U2AF2 RNA splicing
por: Laliotis, Georgios I., et al.
Publicado: (2021)

Retraction Note: AKT3-mediated IWS1 phosphorylation promotes the proliferation of EGFR-mutant lung adenocarcinomas through cell cycle-regulated U2AF2 RNA splicing
por: Laliotis, Georgios I., et al.
Publicado: (2022)

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
por: Chen, Timothy L., et al.
Publicado: (2021)

A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells
por: Hanel, Walter, et al.
Publicado: (2022)

Sjögren’s syndrome and Neuromyelitis Optica spectrum disorders (NMOSD) – a case report and review of literature
por: Jayarangaiah, Apoorva, et al.
Publicado: (2014)

Novel targeted therapies for mantle cell lymphoma
por: Alinari, Lapo, et al.
Publicado: (2012)

Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
por: Jain, Neeraj, et al.
Publicado: (2023)

The Application of Metabolomics in Recent Colorectal Cancer Studies: A State-of-the-Art Review
por: Gold, Andrew, et al.
Publicado: (2022)

Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents
por: Faisal, Muhammad Salman, et al.
Publicado: (2023)

Emerging therapies in mantle cell lymphoma
por: Hanel, Walter, et al.
Publicado: (2020)

Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies
por: Hanel, Walter, et al.
Publicado: (2021)

Iatrogenic Cushing syndrome and adrenal insufficiency during concomitant therapy with ritonavir and fluticasone
por: Epperla, Narendranath, et al.
Publicado: (2015)

Survival of patients with transformed follicular lymphoma in the United States: a multiple cohort study
por: Vaughn, John L., et al.
Publicado: (2023)

Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma
por: Zhao, Xiaohong, et al.
Publicado: (2021)

P1071: COMBINATION OF PD-1 INHIBITION WITH IMMUNOMODULATORY DRUG TREATMENT IN HODGKIN AND LARGE B-CELL LYMPHOMA: RESULTS FROM A PHASE I/II STUDY
por: Bond, David, et al.
Publicado: (2023)

An unusual occurrence: a case of venous thromboembolism in pregnancy associated with heterotaxy syndrome
por: Epperla, Narendranath, et al.
Publicado: (2015)

Emerging treatment options for the management of Hodgkin’s lymphoma: clinical utility of nivolumab
por: Bond, David A, et al.
Publicado: (2017)

Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches
por: Hanel, Walter, et al.
Publicado: (2022)

Diagnostic dilemma: late presentation of amelanotic BRAF-negative metastatic malignant melanoma resembling clear cell sarcoma – a case report
por: Wagner, Barrett Parker, et al.
Publicado: (2013)

Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date
por: Sawalha, Yazeed, et al.
Publicado: (2020)

Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant
por: Liu, Qiuying, et al.
Publicado: (2021)

Editorial: Rising Stars in Hematologic Malignancies 2021
por: Qian, Liren, et al.
Publicado: (2022)

Nonbiological factors affecting outcomes in adolescents and young adults with lymphoma
por: Dhir, Aditi, et al.
Publicado: (2023)

COVID-19 IN A PATIENT WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN USE OF IBRUTINIB: NOT THAT RISKY?
por: Dourado, M.L.B.F., et al.
Publicado: (2020)

Recent survival trends in diffuse large B‐cell lymphoma––Have we made any progress beyond rituximab?
por: Epperla, Narendranath, et al.
Publicado: (2020)

Racial and ethnic differences in the utilization of autologous transplantation for lymphoma in the United States
por: Vaughn, John L., et al.
Publicado: (2021)

Transducin b-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma
por: Youssef, Youssef, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a3ohd70834j56i3nbkeipiusot